Parameter | Hazard-ratio | 95 % CI | P-value |
---|---|---|---|
Performance status: | |||
ECOG 0 | 1 | ||
ECOG 1 | 1.75 | 1.12–2.73 | 0.013 |
ECOG 2 | 2.62 | 1.51–4.53 | 0.001 |
ECOG 3 | 9.78 | 4.85–19.73 | <0.001 |
Tumor biology: | |||
HER2+/HR+ | 1 | ||
HER2+/HR− | 1.19 | 0.70–2.04 | 0.514 |
HER2−/HR+ | 2.49 | 1.49–4.18 | 0.001 |
Triple negative | 5.31 | 2.97–9.47 | <0.001 |
Number of previous metastatic CT lines: | |||
0 | 1 | ||
1 or 2 | 1.81 | 1.14–2.86 | 0.012 |
> 2 | 2.57 | 1.57–4.21 | <0.001 |
Brain metastases | 2.26 | 1.57–3.25 | <0.001 |
Subcutaneous metastases | 1.92 | 1.22–3.01 | 0.005 |
Elevated CA 15-3 (cut-off 30 UI/L) | 1.95 | 1.31–2.93 | 0.001 |
Elevated HER2 ECD (cut-off 30 ng/mL) | 2.51 | 1.53–4.12 | <0.001 |
Elevated S100ß (cut-off 0.12 μg/L) | 1.93 | 1.05–3.54 | 0.033 |